Literature DB >> 12754745

BCL-2 family proteins in peripheral T-cell lymphomas: correlation with tumour apoptosis and proliferation.

George Z Rassidakis1, Dan Jones, Raymond Lai, Preetha Ramalingam, Andreas H Sarris, Timothy J McDonnell, L Jeffrey Medeiros.   

Abstract

The present study investigated expression levels of the anti-apoptotic proteins BCL-2, BCL-XL and MCL-1 and the pro-apoptotic proteins BAX and BCL-XS in a series of 112 peripheral T-cell lymphomas (PTCLs) classified according to the WHO classification. Using immunohistochemical methods and a 10% cut-off, each protein was detected in a subset of PTCLs: BCL-2 in 46%, BCL-XS in 49%, BAX in 57%, BCL-XL in 57%, and MCL-1 in 65%. The mean percentage of positive cells for these proteins varied significantly among the PTCL types. Only two types of PTCL, ALK-positive anaplastic large cell lymphoma (ALCL) and enteropathy-type T-cell lymphoma, had a distinctive pattern of expression; all were BCL-2-negative and MCL-1-positive. The mean percentage of BAX-positive and BCL-XS-positive tumour cells was higher in ALK-positive ALCL than in ALK-negative ALCL or other types of PTCL (p = 0.06 and p = 0.01, respectively, Kruskal-Wallis test). MCL-1 was detected significantly more frequently (p = 0.01, chi-square test) and at higher levels (p = 0.0001, Kruskal-Wallis test) in ALK-positive ALCL and ALK-negative ALCL than in other PTCL types. The apoptotic rate, evaluated by the TUNEL assay, correlated inversely with BCL-2 expression (p = 0.035). The proliferation index, assessed by the MIB-1 antibody, correlated with expression levels of MCL-1 (R = 0.42, p = 0.003), BCL-2 (R = 0.32, p = 0.027), BAX (R = 0.33, p = 0.014), and BCL-XL (R = 0.34, p = 0.015) (Spearman rank). In conclusion, BCL-2 family proteins are expressed by a subset of PTCLs and their levels correlate with some histological types, apoptotic rate, and proliferation index. Expression of these proteins may explain the poor response of many types of PTCL to standard chemotherapy. These proteins may also provide novel targets for experimental therapy. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12754745     DOI: 10.1002/path.1346

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  20 in total

1.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

Review 2.  The role of aberrant proteolysis in lymphomagenesis.

Authors:  Anagh A Sahasrabuddhe; Kojo S J Elenitoba-Johnson
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

3.  Re-activation of mitochondrial apoptosis inhibits T-cell lymphoma survival and treatment resistance.

Authors:  S Spinner; G Crispatzu; J-H Yi; E Munkhbaatar; P Mayer; U Höckendorf; N Müller; Z Li; T Schader; H Bendz; S Hartmann; M Yabal; K Pechloff; M Heikenwalder; G L Kelly; A Strasser; C Peschel; M-L Hansmann; J Ruland; U Keller; S Newrzela; M Herling; P J Jost
Journal:  Leukemia       Date:  2016-03-08       Impact factor: 11.528

Review 4.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Authors:  Y Fernández-Marrero; S Spinner; T Kaufmann; P J Jost
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

5.  Biomarker-driven strategy for MCL1 inhibition in T-cell lymphomas.

Authors:  Raphael Koch; Amanda L Christie; Jennifer L Crombie; Adam C Palmer; Deborah Plana; Kay Shigemori; Sara N Morrow; Alexandria Van Scoyk; Wenchao Wu; Elizabeth A Brem; J Paul Secrist; Lisa Drew; Alwin G Schuller; Justin Cidado; Anthony Letai; David M Weinstock
Journal:  Blood       Date:  2018-11-29       Impact factor: 22.113

6.  Expression of serine 194-phosphorylated Fas-associated death domain protein correlates with proliferation in B-cell non-Hodgkin lymphomas.

Authors:  Elias Drakos; Vasiliki Leventaki; Vasileios Atsaves; Ellen J Schlette; Pei Lin; Francisco Vega; Roberto N Miranda; Francois-Xavier Claret; L Jeffrey Medeiros; George Z Rassidakis
Journal:  Hum Pathol       Date:  2011-02-11       Impact factor: 3.466

7.  Crizotinib (PF-2341066) induces apoptosis due to downregulation of pSTAT3 and BCL-2 family proteins in NPM-ALK(+) anaplastic large cell lymphoma.

Authors:  Farid Saei Hamedani; Munevver Cinar; Zhicheng Mo; Melissa A Cervania; Hesham M Amin; Serhan Alkan
Journal:  Leuk Res       Date:  2014-01-08       Impact factor: 3.156

8.  Spectrum of CD30+ lymphoid proliferations in the eyelid lymphomatoid papulosis, cutaneous anaplastic large cell lymphoma, and anaplastic large cell lymphoma.

Authors:  R Krishna Sanka; Ralph C Eagle; Ted H Wojno; Kenneth R Neufeld; Hans E Grossniklaus
Journal:  Ophthalmology       Date:  2009-12-06       Impact factor: 12.079

9.  Prognostic significance of cell proliferation and apoptosis-regulating proteins in Epstein-Barr Virus positive and negative pediatric non-Hodgkin's lymphoma.

Authors:  Safiye Aktaş; Aydanur Kargi; Nur Olgun; Gulden Diniz; Ayşe Erbay; Canan Vergin
Journal:  Pathol Oncol Res       Date:  2009-09       Impact factor: 3.201

Review 10.  From empiric to mechanism-based therapy for peripheral T cell lymphoma.

Authors:  Andrew M Intlekofer; Anas Younes
Journal:  Int J Hematol       Date:  2014-02-08       Impact factor: 2.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.